The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT

Bone Marrow Transplantation

Volumn 43, Issue 7, 2009, Pages 539-545

  Vangsted, A J ^a,b   Klausen, T W ^b   Ruminski, W ^c   Gimsing, P ^d   Andersen, N F ^e   Gang, A O ^b   Abildgaard, N ^f   Knudsen, L M ^f   Nielsen, J L ^e   Gregersen, H ^g   Vogel, U ^c,h,i  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NATIONAL RESEARCH CENTRE FOR THE WORKING ENVIRONMENT   (Denmark)

^d Rigshospitalet   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f ODENSE UNIVERSITY HOSPITAL   (Denmark)

^g AALBORG UNIVERSITY HOSPITAL   (Denmark)

^h TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

ⁱ ROSKILDE UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BETA 2 MICROGLOBULIN; CREATININE; CYCLOOXYGENASE 2; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; MELPHALAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; VINCRISTINE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; AUTOTRANSPLANTATION; GENETICS; HAPLOTYPE; MIDDLE AGED; MULTIVARIATE ANALYSIS; STEM CELL TRANSPLANTATION; SURVIVAL;

AGED; FEMALE; HAPLOTYPES; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 64949158459     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.351     Document Type: Article

References (29)

1. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004; 25: 280-288.
2. Naugler WE, Karin M. NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev 2008; 18: 19-26.
3. Ray DM, Bernstein SH, Phipps RP. Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands. Clin Immunol 2004; 113: 203-213.
4. El Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
5. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 2003; 63: 3560-3566.
6. Howell WM, Rose-Zerilli MJ. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Fam Cancer 2006; 5: 143-149.
7. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT et al. Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 2006; 7: 27-38.
8. Zhang X, Miao X, Tan W, Ning B, Liu Z, Hong Y et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005; 129: 565-576.
9. Vangsted A, Gimsing P, Klausen TW, Nexo BA, Wallin H, Andersen P et al. Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 2007; 120: 1036-1045.
10. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: A population-based study. Nordic Myeloma Study Group. Blood 2000; 95: 7-11.
11. Lenhoff S, Hjorth M, Westin J, Brinch L, Backstrom B, Carlson K et al Impact of age on survival after intensive therapy for multiple myeloma: A population-based study by the Nordic Myeloma Study Group. Br J Haematol 2006; 133: 389-396.
12. Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G et al. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone. Cancer 2008; 112: 129-135.
13. Vogel U, Christensen J, Dybdahl M, Friis S, Hansen RD, Wallin H et al Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat Res 2007; 624: 88-100.
14. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
15. Saber AT, Nielsen LR, Dictor M, Hagmar L, Mikoczy Z, Wallin H. K-ras mutations in sinonasal adenocarcinomas in patients occupationally exposed to wood or leather dust. Cancer Lett 1998; 126: 59-65.
16. Vogel U, Christensen J, Wallin H, Friis S, Nexo BA, Tjonneland A. Polymorphisms in COX-2, NSAID use and risk of basal cell carcinoma in a prospective study of Danes. Mutat Res 2007; 617: 138-146.
17. Li ZW, Dalton WS. Tumor microenvironment and drug resistance in hematologic malignancies. Blood Rev 2006; 20: 333-342.
18. Costes V, Portier M, Lu ZY, Rossi JF, Bataille R, Klein B. Interleukin-1 in multiple myeloma: Producer cells and their role in the control of IL-6 production. Br J Haematol 1998; 103: 1152-1160.
19. Lacy MQ, Donovan KA, Heimbach JK, Ahmann GJ, Lust JA. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 1999; 93: 300-305.
20. Xiong Y, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ et al. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 2006; 26: 83-95.
21. Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY et al Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002; 123: 1793-1803.
22. Chen H, Wilkins LM, Aziz N, Cannings C, Wyllie DH, Bingle C et al. Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet 2006; 15: 519-529.
23. Lind H, Haugen A, Zienolddiny S. Differential binding of proteins to the IL1B-31 T/C polymorphism in lung epithelial cells. Cytokine 2007; 38: 43-48.
24. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007; 8: 942-949.
25. Nakahara T, Urabe K, Fukagawa S, Uchi H, Inaba K, Furue M et al. Engagement of human monocyte-derived dendritic cells into interleukin (IL)-12 producers by IL-1beta + interferon (IFN)-gamma. Clin Exp Immunol 2005; 139: 476-482.
26. Motta MR, Castellani S, Rizzi S, Curti A, Gubinelli F, Fogli M et al Generation of dendritic cells from CD14+ monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. Br J Haematol 2003; 121: 240-250.
27. Mazur G, Bogunia-Kubik K, Wrobel T, Karabon L, Polak M, Kuliczkowski K et al. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 2005; 96: 241-246.
28. Zheng C, Huang DR, Bergenbrant S, Sundblad A, Osterborg A, Bjorkholm M et al. Interleukin 6, tumour necrosis factor alpha, interleukin 1beta and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 2000; 109: 39-45.
29. Prince HM, Mileshkin L, Roberts A, Ganju V, Underhill C, Catalano J et al. A multicenter phase II trial of thalidomide and celecoxibfor patients with relapsed and refractory multiple myeloma. Clin Cancer Res 2005; 11: 5504-5514.